CervoMed management will present at the H.C. Wainwright Neuro Perspectives Summit on June 15, 2026.
Quiver AI Summary
CervoMed Inc., a biotechnology company focused on developing treatments for age-related brain disorders, announced its management will engage in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026. The discussion will highlight CervoMed’s lead drug candidate, neflamapimod, which targets neuroinflammation and neurodegeneration. The company has recently completed a Phase 2b trial in patients with dementia with Lewy bodies (DLB) and has aligned with the FDA on a potential registration path for neflamapimod in DLB. Additionally, CervoMed has completed enrollment for a Phase 2a trial in another condition and anticipates interim data soon. The webcast of the chat will be available on the CervoMed website.
Potential Positives
- CervoMed is participating in a prominent investor summit, enhancing its visibility and outreach to potential investors.
- The company has announced alignment with the FDA on a potential registration path for its lead drug candidate, neflamapimod, in Dementia with Lewy Bodies (DLB), signaling progress in its development strategy.
- Completion of enrollment in the ongoing Phase 2a clinical trial for neflamapimod in nfvPPA positions the company for future data insights, which could influence investor confidence and interest.
Potential Negatives
- The company is still in the clinical stages of development, with its lead drug candidate not yet approved for market, indicating uncertainty in the timeline for potential revenues.
- The initiation of a critical Phase 3 trial is contingent on establishing a partnership or obtaining additional financing, suggesting potential financial or operational challenges.
- The mention of having just completed enrollment for a Phase 2a trial and the waiting period for interim data could raise concerns about the speed of progress in advancing their drug candidates.
FAQ
What is CervoMed Inc. known for?
CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related brain disorders.
When will CervoMed participate in the H.C. Wainwright Summit?
CervoMed will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026.
How can I access the webcast of the fireside chat?
The webcast can be accessed via the Investor section of the CervoMed website at https://www.cervomed.com/.
What is neflamapimod?
Neflamapimod is CervoMed's lead drug candidate targeting neuroinflammation and neurodegeneration in age-related brain disorders.
What trials is CervoMed currently conducting?
CervoMed is conducting Phase 2b and Phase 2a trials for neflamapimod in DLB and nfvPPA, respectively.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026.
Presentation Details
Format: Fireside Chat
Date: Monday, June 15, 2026
Time: 7:00 – 7:30 AM ET
Webcast Link:
https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ .
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Contacts
Media:
Lisa Guiterman
Biongage Communications
[email protected]
202-330-3431
Investor Relations:
Argot Partners
[email protected]
212-600-1902
